Literature DB >> 17182504

High dose controlled-release oxycodone in hospice care.

Michaela Bercovitch1, Abraham Adunsky.   

Abstract

Controlled-release oxycodone (OxyContin) is commonly used for pain relief in terminal cancer. This opioid may be considered as a treatment option for patients who prefer oral pain control, but who are unwilling to take oral morphine sulphate or cannot tolerate its side effects. However, little is documented about the use of high doses of this drug in terminal cancer patients. The purpose of this study was to investigate the clinical characteristics of terminally ill hospice inpatients treated with OxyContin for pain, and to compare those patients receiving high-dose OxyContin (150 mg/day) with patients taking low and more typical doses. This retrospective chart analysis with parallel groups included records of 97 consecutive terminal cancer patients. We recorded clinical and demographic data, as well as data regarding daily doses, rescue doses and parameters associated with quality of life. The mean daily OxyContin dose was 78.6 mg per day for all patients. Only 18 (18.55%) patients were treated with high doses (mean daily dose 231.1 mg). No statistically significant correlations were found between any of the deomographic parameters and dose ranges, with the exception of patients with painful bony metastases who consumed significantly higher doses (p = 0.008). No differences were observed in sleep quality or mood as a factor of OxyContin doses. However, compared with patients receiving low-dose (OR 1.0), patients treated with moderate and high doses maintained Karnofsky scores higher than 40 points most of the time (OR = 3.77, CI 1.1-13.0 and OR 4.95, CI 0.8-29.9, respectively). Survival was not related to OxyContin doses (Log Rank test, p = 0.12; Breslow test, p = 0.37). We conclude that the use of high dose OxyContin for terminal cancer pain management is safe, efficient, and unrelated to shorter survival times. The results suggest that health care professionals may use higher OxyContin doses, when indicated, to enable better pain relief and quality end-of-life care.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17182504

Source DB:  PubMed          Journal:  J Pain Palliat Care Pharmacother        ISSN: 1536-0288


  13 in total

1.  Opioids have no negative effect on the survival time of patients with advanced lung cancer in an acute care hospital.

Authors:  Seigo Minami; Kosuke Fujimoto; Yoshitaka Ogata; Suguru Yamamoto; Kiyoshi Komuta
Journal:  Support Care Cancer       Date:  2015-01-07       Impact factor: 3.603

2.  G protein-gated inwardly rectifying potassium (KIR3) channels play a primary role in the antinociceptive effect of oxycodone, but not morphine, at supraspinal sites.

Authors:  Atsushi Nakamura; Masahide Fujita; Hiroko Ono; Yoshie Hongo; Tomoe Kanbara; Koichi Ogawa; Yasuhide Morioka; Atsushi Nishiyori; Masahiro Shibasaki; Tomohisa Mori; Tsutomu Suzuki; Gaku Sakaguchi; Akira Kato; Minoru Hasegawa
Journal:  Br J Pharmacol       Date:  2014-01       Impact factor: 8.739

3.  High doses of oxycodone-naloxone combination may provide poor analgesia.

Authors:  Sebastiano Mercadante; Patrizia Ferrera; Claudio Adile
Journal:  Support Care Cancer       Date:  2011-06-09       Impact factor: 3.603

4.  Switching from oxycodone to methadone in advanced cancer patients.

Authors:  Sebastiano Mercadante; Patrizia Ferrera; Patrizia Villari; Claudio Adile; Alessandra Casuccio
Journal:  Support Care Cancer       Date:  2011-09-07       Impact factor: 3.603

5.  Controlled-release oxycodone for the treatment of bortezomib-induced neuropathic pain in patients with multiple myeloma.

Authors:  Claudio Cartoni; Gregorio Antonio Brunetti; Vincenzo Federico; Fabio Efficace; Sara Grammatico; Andrea Tendas; Laura Scaramucci; Luca Cupelli; Gianna Maria D'Elia; Andrea Truini; Pasquale Niscola; Maria Teresa Petrucci
Journal:  Support Care Cancer       Date:  2012-06-15       Impact factor: 3.603

6.  Effects of high-dose opioid analgesia on survival, pain relief, quality of life and adverse drug reactions in cancer and neuropathic pain patients: a retrospective cohort study in real-world clinical practice.

Authors:  Xing Hao; Yiting Zhou; Yingxian Ling; Hirotsugu Miyoshi; Masahiko Sumitani; Kwok Ying Chan; Hue Jung Park; Zhiying Feng; Yuefeng Rao
Journal:  Ann Transl Med       Date:  2022-09

7.  Differential activation of the μ-opioid receptor by oxycodone and morphine in pain-related brain regions in a bone cancer pain model.

Authors:  Atsushi Nakamura; Minoru Hasegawa; Kazuhisa Minami; Tomoe Kanbara; Takako Tomii; Atsushi Nishiyori; Minoru Narita; Tsutomu Suzuki; Akira Kato
Journal:  Br J Pharmacol       Date:  2013-01       Impact factor: 8.739

8.  Oxycodone controlled-release as first-choice therapy for moderate-to-severe cancer pain in Italian patients: results of an open-label, multicentre, observational study.

Authors:  Barbara Silvestri; Elena Bandieri; Salvatore Del Prete; Giovanni Pietro Ianniello; Giuseppe Micheletto; Mario Dambrosio; Giovanni Sabbatini; Luigi Endrizzi; Alessandro Marra; Enrico Aitini; Angioletta Calorio; Ferdinando Garetto; Giuseppe Nastasi; Francovito Piantedosi; Vincenzo Sidoti; Piergiorgio Spanu
Journal:  Clin Drug Investig       Date:  2008       Impact factor: 2.859

9.  Cancer pain management-current status.

Authors:  Deepak Thapa; V Rastogi; Vanita Ahuja
Journal:  J Anaesthesiol Clin Pharmacol       Date:  2011-04

10.  Pain treatment with high-dose, controlled-release oxycodone: an Italian perspective.

Authors:  Fabio Ferrarese; Gioia Becchimanzi; Massimo Bernardo; Maria Anna Conte; Angela Gioia; Davide Ottaviani; Rosa Palomba; Gianfranco Pedelini; Laura Rigotti; Elvira Scelzi
Journal:  Ther Clin Risk Manag       Date:  2008-08       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.